Literature DB >> 2149026

Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer.

E Boven1, H M Schlüper, C A Erkelens, H M Pinedo.   

Abstract

Eight human ovarian cancer lines grown in nude mice were used to compare the activity of doxorubicin, epirubicin, mitoxantrone and menogaril. The tumour lines were different in histological subtype, tumour doubling time and sensitivity to doxorubicin. The compounds were administered intravenously at the maximum tolerated dose twice with one week in between when tumours measured 50-150 mm3. Growth inhibition greater than 50% was obtained for doxorubicin in 8/8, for epirubicin in 4/8, for mitoxantrone in 5/8 and for menogaril in 2/8 tumour lines. In MRI-H-207, doxorubicin was the only drug able to induce complete remission. Compared with doxorubicin, mitoxantrone and menogaril were given in proportionally higher doses than those administered to patients, but did not result in superior antitumour activity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149026     DOI: 10.1016/0277-5379(90)90626-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.

Authors:  Kai Xiao; Juntao Luo; Yuanpei Li; Joyce S Lee; Gabriel Fung; Kit S Lam
Journal:  J Control Release       Date:  2011-07-19       Impact factor: 9.776

Review 2.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  L-histidine-based pH-sensitive anticancer drug carrier micelle: reconstitution and brief evaluation of its systemic toxicity.

Authors:  Kyung T Oh; Eun Seong Lee; Dongin Kim; You Han Bae
Journal:  Int J Pharm       Date:  2008-03-13       Impact factor: 5.875

4.  Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles.

Authors:  Mohammad H El-Dakdouki; Jingguang Xia; David C Zhu; Herbert Kavunja; Jessica Grieshaber; Sandra O'Reilly; J Justin McCormick; Xuefei Huang
Journal:  ACS Appl Mater Interfaces       Date:  2013-12-12       Impact factor: 9.229

5.  Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening.

Authors:  E Boven; H M Pinedo; A H van Hattum; P G Scheffer; W H Peters; C A Erkelens; H M Schlüper; C M Kuiper; J van Ark-Otte; G Giaccone
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

6.  A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.

Authors:  P H Houba; E Boven; I H van der Meulen-Muileman; R G Leenders; J W Scheeren; H M Pinedo; H J Haisma
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

7.  The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.

Authors:  E Boven; H R Hendriks; C A Erkelens; H M Pinedo
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

8.  The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

Authors:  E Boven; H Schipper; C A Erkelens; S A Hatty; H M Pinedo
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.